EndNote 1 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Hepatol. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes.
Hepatology ; 73— Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. The rise and fall of the metabolic syndrome.
Transient disappearance of traumatic microbleeds on susceptibility weighted imaging in rats
Diabetologia ; — Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care ; — Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
- Pleomorphic adenoma parotid radiology
- A prosztatitis kezelés problémái
- A prosztatagyulladás jelei a kezelés
Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol.
Mol Carcinog. The rs EK variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology ; — Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis.
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease — MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther.
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy.
Prostate MRI — Zonal Anatomy Prosztatával ha nincs sürgetés a vizeletre
Eur J Radiol. Steatosis hepatis — a challenge? Accuracy of MR elastography normal prostate volume radiology anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis.
J Magn Reson Imaging ; — The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.
High Level Abstract Background The human population residing in monazite bearing Kerala coast are exposed to chronic low dose and low dose rate external gamma radiation due to Th deposits in its beach sand. This area serves as an ideal source for conducting large-scale epidemiological studies for assessing risk of low dose and low dose rate radiation exposure on human population. HLNRAs were further stratified into three dose groups of 1. Methodology Consecutive newborns were monitored from two hospital units located in the study area for congenital malformations. Referred CHD cases among the newborns screened were confirmed by conducting investigations such as pulse oximetry, chest X-ray, electrocardiogram and echocardiogram etc.
Utility and appropriateness of the fatty liver inhibition of progression FLIP algorithm and steatosis, activity, and fibrosis SAF score in the evaluation of biopsies of nonalcoholic fatty liver disease. Prediabetes: a high-risk state for diabetes developing.
Low Dose Rate Latest Research Papers | ScienceGate
Lancet ; — Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes ; — Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Fatty liver disease determines the progression of coronary artery calcification in a metabolically healthy obese population.
Ultrasound Estimated Post-Void Residual Bladder
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes — Diabetes Care ; 41 Suppl 1 : S28—S Health care professional guideline — the diagnosis, antihyperglicemic treatment and care of diabetes mellitus in adults.
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease NAFLD. Advances in the pathogenesis of non alcoholic fatty liver disease. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
Atherosclerosis ; — Link between non-alcoholic fatty liver disease and atrial fibrillation: a systematic review and meta-analysis. Normal prostate volume radiology ; 9: e Non-alcoholic fatty liver disease and hepatocellular carcinoma — Non alcoholic fatty liver.
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. Unravelling the pathogenetic mechanisms of fructose consumption as multiple hit in the pathogenesis and progression of non-alcoholic fatty liver disease.
Diabetologia ; 60 Suppl 1 : S6. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis LEAN : a multicentre, double-blind, randomised, placebo-controlled phase 2 study. JAMA ; — Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ ; c Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.
Curr Vasc Pharmacol.
- Calcificazioni prostata onde d'urto
- Amikor fibrózis és prosztata kövek
- A prosztatitis fájdalom szindróma kezelése
Non-alcoholic fatty liver disease NAFLD and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients ; 5: — Prostatitis húzza a fájdalmat fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases.
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab.